Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 187-194

  Zhou, Yanchen ^a,b   Agudelo, Juliet ^a   Lu, Kai ^a   Goetz, David H ^a   Hansell, Elizabeth ^b   Chen, Yen Ting ^c   Roush, William R ^c   McKerrow, James ^b   Craik, Charles S ^a   Amberg, Sean M ^d   Simmons, Graham ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d SIGA Technologies Incorporated   (United States)

Author keywords

Antiviral; Dual envelope pseudovirion assay; High throughput screening; HTS; Inhibitors of SARS CoV entry; Pseudovirus

Indexed keywords

ANTI MURINE LEUKEMIA VIRUS ANTIBODY; ANTIVIRUS AGENT; LEUPEPTIN; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; ST 193; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS SPIKE PROTEIN; WRR 182; WRR 183; WRR 485; WRR 486; WRR 487; WRR 488; WRR 492; WRR 493; WRR 495; WRR 496; Z PHE PHE FMK; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DUAL ENVELOPE PSEUDOVIRION ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; SARS VIRUS; VIRUS CULTIVATION; VIRUS INTERNALIZATION;

CORONAVIRUS; SARS CORONAVIRUS;

EID: 80054867941     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.016     Document Type: Article

References (27)

1. Barnard D.L., Day C.W., Bailey K., Heiner M., Montgomery R., Lauridsen L., Chan P.K., Sidwell R.W. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 2006, 17:275-284.
2. Chandran K., Sullivan N.J., Felbor U., Whelan S.P., Cunningham J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308:1643-1645.
3. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944.
4. Deming D., Sheahan T., Heise M., Yount B., Davis N., Sims A., Suthar M., Harkema J., Whitmore A., Pickles R., West A., Donaldson E., Curtis K., Johnston R., Baric R. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006, 3:e525.
5. Ebert D.H., Deussing J., Peters C., Dermody T.S. Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J. Biol. Chem. 2002, 277:24609-24617.
6. Garcia J.M., Gao A., He P.L., Choi J., Tang W., Bruzzone R., Schwartz O., Naya H., Nan F.J., Li J., Altmeyer R., Zuo J.P. High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay. Antivirial Res. 2009, 81:239-247.
7. Gilbert J.M., Bates P., Varmus H.E., White J.M. The receptor for the subgroup A avian leukosis-sarcoma viruses binds to subgroup A but not to subgroup C envelope glycoprotein. J. Virol. 1994, 68:5623-5628.
8. Glowacka I., Bertram S., Müller M.A., Allen P., Soilleux E., Pfefferle S., Steffen I., Tsegaye T.S., He Y., Gnirss K., Niemeyer D., Schneider H., Drosten C., Pohlmann S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 2011, 85:4122-4134.
9. Goetz D.H., Choe Y., Hansell E., Chen Y.T., McDowell M., Jonsson C.B., Roush W.R., McKerrow J., Craik C.S. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry 2007, 46:8744-8752.
10. Golda A., Pyrc K. Recent antiviral strategies against human coronavirus-related respiratory illnesses. Curr. Opin. Pulm. Med. 2008, 14:248-253.
11. Huang I.C., Bosch B.J., Li F., Li W., Lee K.H., Ghiran S., Vasilieva N., Dermody T.S., Harrison S.C., Dormitzer P.R., Farzan M., Rottier P.J., Choe H. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol. Chem. 2006, 281:3198-3203.
12. Kam Y.W., Okumura Y., Kido H., Ng L.F., Bruzzone R., Altmeyer R. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One 2009, 4:e7870.
13. Larson R.A., Dai D., Hosack V.T., Tan Y., Bolken T.C., Hruby D.E., Amberg S.M. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 2008, 82:10768-10775.
14. Liu L., Fang Q., Deng F., Wang H., Yi C.E., Ba L., Yu W., Lin R.D., Li T., Hu Z., Ho D.D., Zhang L., Chen Z. Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. J. Virol. 2007, 81:4694-4700.
15. Pager C.T., Dutch R.E. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J. Virol. 2005, 79:12714-12720.
16. Pager C.T., Craft W.W., Patch J., Dutch R.E. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. Virology 2006, 346:251-257.
17. Rockx B., Corti D., Donaldson E., Sheahan T., Stadler K., Lanzavecchia A., Baric R. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 2008, 82:3220-3235.
18. Roush W.R., González F.V., McKerrow J.H., Hansell E. Design and synthesis of dipeptidyl alpha', beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. Lett. 1998, 8:2809-2812.
19. Salvador B., Zhou Y., Michault A., Muench M.O., Simmons G. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 2009, 393:33-41.
20. Schornberg K., Matsuyama S., Kabsch K., Delos S., Bouton A., White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 2006, 80:4174-4178.
21. Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002, 76:2518-2528.
22. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA 2004, 101:4240-4245.
23. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA 2005, 102:11876-11881.
24. Simmons G., Bertram S., Glowacka I., Steffen I., Chaipan C., Agudelo J., Lu K., Rennekamp A.J., Hofmann H., Bates P., Pohlmann S. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology 2011, 413:265-274.
25. WHO, 2003. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS) [monograph on the Internet].
26. York J., Dai D., Amberg S.M., Nunberg J.H. PH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 2008, 82:10932-10939.
27. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.